Jeil Pharmaceutical

KSC:271980 · KR7271980005

PharmaceuticalsSmall

360

Medium confidence — indicative

Value54

Profit price23

Cash yield44

Owner Earnings Yield86

Dividend Yield1

Sales & asset price80

Price/Sales89

EV / Gross Profit89

Price/Book62

Quality55

Returns on capital85

Return on Capital80

Cash Return on Capital85

Return on Equity89

Profit margins76

EBIT Margin63

Gross Profitability88

Cash backing29

Cash Conversion1

Accruals14

Owner Earnings Margin73

Growth60

Sales growth3

Profit growth67

Profit Growth27

Long-Term EPS Growth74

Owner Earnings Growth100

Reinvestment32

Price momentum37

Safety56

Debt load49

Debt serviceability73

Refinancing84

Debt Payback62

Liquidity48

Sentiment46

Analyst ratings—

Expectations trend—

Market mood1

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Jeil Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Employees52

Websitejeilpharm.co.kr

ISINKR7271980005

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

UrologyNeurologyCardiovascularEndocrinologyCentral Nervous SystemOncologyBiotechnologyManufacturing

Description

Analysis

Middle-of-the-road

Jeil Pharmaceutical Co.,Ltd is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is attractive. You pay 5.8× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Jeil Pharmaceutical with its peers

Jeil Pharma

KSC:002620

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Hana Pharm

KSC:293480

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Shinpoong Pharmaceutical

KSC:019170

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Boryung

KSC:003850

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Hanall Biopharma

KSC:009420

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

JW Pharmaceutical

KSC:001060

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →